U.S. Fintech Self Raises $20 Million Through Series C Funding Round Co-Led By Altos Ventures & Conductive Ventures
Self (formerly Self Lender), a U.S.-based fintech startup offering people a way to build their credit while also saving money, announced on Wednesday it raised $20 million through its Series C funding round, which was co-led by Altos Ventures & Conductive Ventures. Founded in 2015,... Read More
Enigma MPC, formerly known as Newton Security Labs, has settled charges leveled by the Enforcement Division of the Securities and Exchange Commission regarding an initial coin offering (ICO). The SEC had accused Enigma of conducting an unregistered securities offering. Enigma raised $45 million by selling... Read More
The post ICO Issuer Enigma MPC Settles with the SEC, Will Return Money to Investors, appeared first on Crowdfund Insider.
Swedish Banking Group Northmill Appoints Former Klarna Product Manager Arash Eftekhari As New Chief Product Officer
Northmill, a banking group based in Sweden, announced on Wednesday it has appointed former Klarna product manager, Arash Eftekhari, as its new Chief Product Officer. According to Northmill, Eftekhari will lead product development aiming to strengthen the connection between the product and the user. Northmill... Read More
Openfinance, a registered alternative trading system (ATS) that is trading marketplace for digital assets, has announced the listing of Lottery.com‘s LDCC token. The digital asset is available for all US investors – not just accredited individuals. LDCC is the security token offered by Lottery.com. The... Read More
The post Open for Trading: Openfinance Lists LDCC Token from Lottery.com appeared first on Crowdfund Insider.
Global payables platform Tipalti announced on Wednesday it has surpassed $10 billion in annual transactions. The company reported the news coincides with it exceeding 900 customers, once again doubling new customer bookings in 2019. Tipalti also added 65 new team members during the second half... Read More
The post Tipalti’s New Milestone: Surpasses $10 Billion in Annual Transactions appeared first on Crowdfund Insider.
Japan’s Mitsubishi UFJ Financial Group Inc. (MUFJ) is set to invest more than $700 million in Southeast Asian ride-hailing giant Grab. According to Bloomberg, the MUFG intends to market a range of financial services from insurance to loans to Grab’s users. Founded in 2012, Grab describes... Read More
The post Japan’s MUFG to Reportedly Invest More Than $700 in South Asian Ride-Hailing Service Grab appeared first on Crowdfund Insider.
Ally Financial Inc. (NYSE: ALLY) announced on Wednesday it has entered into a definitive agreement to acquire CardWorks, a U.S. credit card issuer focused on the non-prime segment with a complementary full-spectrum unsecured servicing operation that includes third-party servicing and recovery capabilities, in a transaction... Read More
The post Ally Financial Set to Acquire CardWorks For $2.65 Billion appeared first on Crowdfund Insider.
Recently, the Securities and Exchange Commission (SEC) proposed changes to the definition of “accredited investor.” Many issuers and intermediaries hoped the SEC would expand the definition of “accredited investor,” to include qualitative conditions, such as education, or by lowering quantitative thresholds, such as income and... Read More
The post Perspective: Don’t Blame the SEC, the Definition of “Accredited Investor” Was Never the Problem appeared first on Crowdfund Insider.
Coinbase, a leading digital asset marketplace, has become the “first pure-play crypto company to be approved as a Visa principal member,” according to a blog post. By becoming a principal member, Coinbase will be able to offer additional services. Principal members may also act as... Read More
The post Coinbase Becomes First Pure-Play Crypto Company to be Approved as a Visa Principal Member appeared first on Crowdfund Insider.
Coinfloor, the “UK’s longest-running Bitcoin exchange,” is targeting retail customers with a new push into consumer-focused trading and investing. In a release, the company said it wanted to make “Bitcoin buying boring” and banish the “Coin BS”. Coinfloor added that it will launch a range... Read More
The post Bitcoin Exchange Coinfloor Targets Retail Consumers in Push to Promote Crypto to Wider Audience appeared first on Crowdfund Insider.
Celsius Network, a cryptocurrency lending, and borrowing platform, announces on Wednesday it is now offering users to buy Bitcoin directly within the Celsius mobile app through its new partnership with Simplex, a credit card onramp and offramp service provider. Celsius Network reported that through the... Read More
The post Celsius Network Joins Forces With Simplex to Offer Low Fee BTC Purchase On-Ramp appeared first on Crowdfund Insider.
TSX:MDNA.TO | OTC:MDNAF
On February 13, 2020, Medicenna Therapeutics Corp. (TSX:MDNA.TO) (OTC:MDNAF) announced financial results for the third quarter of fiscal year 2020 that ended Dec. 31, 2019. The company reported a net loss of CAD$2.4 million, or CAD$0.07 per share, compared to a net loss of CAD$1.7 million, or CAD$0.07 per share, for the third quarter of fiscal year 2019. R&D expenses for the three months ending Dec. 31, 2019 were CAD$1.7 million, compared to CAD$1.3 million for the three months ending Dec. 31, 2018. The increase was primarily attributable to increased regulatory costs associated with preparing for the upcoming ‘End-of-Phase 2’ meeting with the FDA along with a lower reimbursement of expenses from the CIPRIT grant partially offset by lower clinical costs due to the completion of enrollment of the Phase 2b trial of MDNA55. G&A expenses for the third quarter of fiscal year 2019 were CAD$0.7 million compared to CAD$0.4 million for the corresponding period in the prior year. The increase in G&A expenses was primarily due to lower reimbursement of expenses from CIPRIT and increased stock-based compensation expenses.
As of Dec. 31, 2019, Medicenna had approximately CAD$7.0 million in cash and cash equivalents. Subsequent to the end of the quarter the company received approximately CAD$0.9 million in proceeds from warrant exercises and there is an additional US$1.4 million remaining available under the CIPRIT grant to be used for the development of MDNA55. We estimate that the company has sufficient capital to fund operations through the end of 2020.
Medicenna had approximately 35.3 million shares outstanding as of Feb. 13, 2020 along with approximately 6.7 million warrants and 4.2 million stock options for a fully diluted share count of approximately 46.2 million.
Highly Encouraging Results for MDNA55 When Comparing with Synthetic Control Arm
On January 13, 2020, Medicenna Therapeutics Corp. announced encouraging data for the company’s Phase 2b clinical trial of MDNA55, an IL-4 targeted toxin, in patients with recurrent glioblastoma (rGBM) when compared to an eligibility-matched arm of control subjects (n=81) who were treated with approved therapies, including Avastin®, lomustine, and temozolomide. The control subjects had similar baseline features as patients treated with MDNA55 including de novo grade IV GBM at 1st or 2nd relapse following standard 1st-line treatments with surgery and radio-chemotherapy, tumors between 1 cm x 1 cm to 4 cm x 4 cm, Karnofsky Performance Status (KPS) of ≥ 70, not eligible for surgery/resection at relapse, and no known mutations of IDH1 and/or IDH2. In this study, survival results for both arms were computed from the date of relapse rather than from the date of treatment, which was how results were previously reported by the company.
The results showed that:
• Median overall survival (mOS) for patients with high expression of IL-4R was 15.8 months for the MDNA55-treated cohort (n=21) compared to 6.2 months for the control arm (n=17).
◦ Note: Medicenna only had access to 40 archived tissue samples for the control arm, thus the percentage of patients in that arm who had high expression of IL-4R (43%) was similar to that seen in the Phase 2b trial (48%).
• For patients with high expression of IL-4R, 12-month OS for the MDNA55-treated cohort was 62% compared to 24% for the control arm.
• When considering all patients, mOS in the MDNA55-treated cohort was 12.4 months compared to 7.7 months in the control arm.
• When considering all patients, 12-month OS for the MDNA55-treated cohort was 53% compared to 25% for the control arm.
We believe this data is very compelling, particularly for those patients with high expression of IL-4R. The company will take this data to the FDA as part of the ‘End-of-Phase 2’ meeting that will be taking place in the second quarter of 2020. At this meeting we expect the agency to provide guidance on the regulatory path forward for MDNA55 as well as if the opportunity exists for accelerated approval.
Synthorx Acquisition Puts Spotlight on Enhanced IL-2’s
On Dec. 9, 2019, SynthoRx, Inc. announced it was being acquired by Sanofi for $68 per share, which represents a fully diluted value for SynthoRx of approximately $2.5 billion. SynthoRx’s lead development candidate, THOR-707, is an interleukin (IL)-2 variant that is pegylated at a specific site to block binding to the IL-2 receptor α chain and extend the half-life. It is currently being studied in a Phase 1 clinical trial as a single agent and will be tested in combination with immune checkpoint inhibitors in future trials. SynthoRx also has additional preclinical cytokine variant programs, including an IL-15 and an IL-10 program.
IL-2 is a 16 kDa protein that activates a wide range of leukocytes, including T cells and natural killer (NK) cells through binding IL-2 receptors (IL-2Rα [CD25], IL-2Rβ [CD122], and IL-2Rγ [CD132]), with the arrangement of these receptors dictating the response seen. Binding of IL-2 to a heterodimer consisting of CD122 and CD132 is of “intermediate affinity’, whereas a heterotrimer consisting of all three IL-2Rs is a ‘high affinity’ complex. The heterotrimer is typically found on activated T cells (including regulatory T cells) while naïve T cells and NK cells only express the heterodimer. Thus, modifying IL-2 signaling to enhance binding to the CD122/CD132 complex could enhance T cell activation while diminishing the effect of regulatory T cells. An enhanced version of IL-2 that exhibited increased affinity to CD122 was first described in 2012 (Levin et al., 2012) and additional work has yielded a family of long-acting ‘IL-2 Superkines’ with enhanced features compared to IL-2.
Medicenna previously presented preclinical data for MDNA19, the company’s lead IL-2 Superkine, that showed the compound has no affinity for CD25, enhanced affinity for CD122, and is active as both a monotherapy and in combination with checkpoint inhibitors. The following figure on the left shows decreased tumor growth in mice treated with MDNA19 (green line) and enhanced anti-tumor activity when MDNA19 is administered along with an α-CTLA4 antibody (blue line). The figure on the right shows that MDNA19 achieves similar efficacy to other MDNA109 family members with less frequent dosing in an aggressive B16F10 melanoma mouse model.
Medicenna will be advancing MDNA19 into clinical development as the lead IL-2 Superkine based on the lack of affinity for CD25 and enhanced affinity for CD122. We believe this is the only enhanced long-acting IL-2 in development that combines both of those characteristics, and it likely has potential in a number of therapeutic applications, including in combination with checkpoint inhibitor therapy, as part of an ‘armed’ oncolytic virus, or as a fusion protein with antibodies or other cytokines. Pre-IND work is continuing on MDNA19 such that it can be advanced into the clinic in 2021.
Valuation and Conclusion
The comparison Medicenna performed with a synthetic control arm highlights the effectiveness of MDNA55 treatment in rGBM patients and shows that it could offer a much better option than currently available therapies for this patient population. We are eager to hear the outcome of the ‘end-of-Phase 2’ meeting with the FDA and while we continue to believe the agency will require a Phase 3 trial prior to approval, we will be very interested to learn about the potential for accelerated approval.
The acquisition of SynthoRx is an intriguing development for Medicenna, particularly the price that Sanofi was willing to pay for a lead compound that just began Phase 1 testing. We estimate that Medicenna is approximately one year behind SynthoRx in the development of MDNA19, however we believe MDNA19 offers a number of attributes that could lead it to becoming a best-in-class molecule. Based on the valuation assigned to SynthoRx we have increased our estimated valuation for MDNA19 and the Superkine platform to CAD$500 million, which has increased our valuation to CAD$13 per share. Following the SynthoRx acquisition the stock has advanced >100%, however we believe there is significant upside potential based on the advancement of both MDNA55 and MDNA19.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.
Rokk3r (OTC: ROKK), a multinational company co-builder, announced on Tuesday its insurance-technology division, Rokk3r Insurtech, has formed a new partnership with insurance Software-as-a-Service provider Genasys to market the company’s services to new target markets. Rokk3r claims that Rokk3r Insurtech has the most complete and advanced... Read More
The post Rokk3r Insurtech Announces Partnership with Insurance SaaS Company Genasys appeared first on Crowdfund Insider.
Fiserv Teams Up with Visa, Samsung, PayCore to Test Using Smartphones as PIN-Entry Devices for Retail Payments
Fiserv, Inc. (NASDAQ: FISV), a leading multinational firm focused on offering financial services technology platforms, has teamed up with Visa, Samsung and PayCore in order to test the use of consumer-grade smartphones as PIN-entry devices for retail sales transactions. The new capability can be accessed... Read More
Cere Network Partners with Blockchain Firm Harmony to Secure Personally Identifiable Information and Link to Fragmented Data Economy
Cere Network revealed on February 18 that it has formed a strategic partnership with Harmony in order to secure personally identifiable information (PII) and link to a fragmented data economy by “co-innovating” with Harmony’s developers and their zero-knowledge proving (ZKP) system. According to a press... Read More
Gpi is Being Used Everywhere, As Swift Handled $77 Trillion in International Payments Messages via the Platform in 2019, Company Executive Confirms
Major bank-to-bank messaging system Swift processed $40 trillion in messaging transactions back in 2018. Significantly, Swift handled $77 trillion in international payments messages via the gpi platform last year, which indicates that the demand for the program is becoming even more firmly established in the... Read More
Commercial Blockchain Developer Lition Confirms that Microsoft has Integrated its DLT-based Solution to its Azure Cloud Marketplace
Lition, the developer of a commercial blockchain network, confirmed on February 18 that tech giant Microsoft has integrated its distributed ledger technology (DLT)-based solution to its Azure cloud marketplace. The integration with Microsoft’s Azure cloud platform notably makes Lition one of the few public (permissionless)... Read More
Standard Chartered Appoints Former Ripple Exec Kahina van Dyke As New Global Head of Digital Channels & Client Data Analytics
Standard Chartered, a UK-based multinational banking and financial services company with $688 billion in assets, announced on Wednesday it has appointed Kahina van Dyke as its new Global Head of Digital Channels and Client Data Analytics. According to Standard Chartered, Kahina joins from Ripple where... Read More
Global financial service platform Kabbage announced on Tuesday its latest data, which polled more than 600 U.S. small business owners, revealed the majority of small businesses believe their revenue growth underperforms their peers. Specifically, 60% of respondents ranked their revenue growth below the 50th percentile... Read More
The post Kabbage’s Latest Data Reveals Small Businesses’ Revenue Growth Is Stronger Than Perceived appeared first on Crowdfund Insider.
European Mobile Based Payment System Trisbee Now Seeking €250,000 Through Equity Crowdfunding Campaign on Seedrs
Trisbee, a European mobile-based payments platform, is now seeking €250,000 through its equity crowdfunding campaign on Seedrs. The platform is currently offering 12.20% in equity at a €1.8 million pre-money valuation. Launched in 2018, Trisbee is seeking to become a completely independent banking and payments... Read More